Aberdeen Group’s Akero Therapeutics AKRO Stock Holding History

Aberdeen Group’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-502,913	Closed	-$23.9M	–	940
2025 Q3	$23.9M	Buy	502,913 +111,313	+28%	+$5.39M	0.04%	371
2025 Q2	$20.9M	Sell	391,600 -15,100	-4%	-$686K	0.04%	398
2025 Q1	$16.5M	Buy	406,700 +136,918	+51%	+$5.8M	0.03%	438
2024 Q4	$7.51M	Buy	269,782 +146,424	+119%	+$4.43M	0.01%	564
2024 Q3	$3.54M	Sell	123,358 -75,879	-38%	-$1.98M	0.01%	703
2024 Q2	$4.67M	Hold	199,237	–	–	0.01%	638
2024 Q1	$5.03M	Buy	199,237 +127,695	+178%	+$3.07M	0.01%	666
2023 Q4	$1.67M	Buy	+71,542	New	+$1.41M	﹤0.01%	787

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Aberdeen Group's AKRO Position: Q4 2025 in Review

Aberdeen Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 502,913 shares — an estimated $23.9M sold.

Aberdeen Group first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $23.9M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Aberdeen Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Aberdeen Group sold 502,913 Akero Therapeutics shares in Q4 2025, an estimated $23.9M.
Aberdeen Group first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
Aberdeen Group's Akero Therapeutics position peaked at $23.9M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.